No Data
Stocks hitting the upper and lower limits before the market.
■ Limit up <4240> Cluster Technology <4506> Sumitomo Pharma ■ Limit down <6836> Plat Home *Includes temporary limit up and down (indicative prices).
Patent Focus = Sumitomo Pharma: Azabicyclo ring derivatives, etc.
Sumitomo Pharma <4506.T> conducts research and development focused on psychiatric and neurological fields as well as cancer. Its main products include the prostate cancer treatment "Orgovix". Optical active azabicyclo ring derivatives (2025060871) that are highly effective anticancer agents, formulations with excellent solubility and tabletability (WO/2025/070617), and a method to non-invasively monitor the state of cells in culture during differentiation from pluripotent stem cells to neural cells in the midbrain floor plate.
The Nikkei average is up by about 20 yen, with the top gainers among the selected stocks being Sumitomo Pharma, TOTO, NEC, ETC.
On the 30th at around 11 AM, the Nikkei Stock Average was trading around 35,860 yen, up about 20 yen compared to the previous trading day. At 9:09 AM, it reached 36,023.24 yen, up 183.25 yen. After the buying frenzy, there were moments of retraction as there were few clues, and the exchange rate was also moving in the direction of a stronger yen. Afterward, it remained in a range near the previous trading day's closing price. Among the stocks listed in the Nikkei Average, Sumitomo Pharma <4506.T> and TOTO <5332> ranked high in terms of price increase percentage.
Sumitomo Pharma --- reached the upper limit of price increase, significantly revised upwards beyond expectations, making an impact.
The stock reached its upper limit. The upward revision of the financial results for the fiscal year ending in March 2025 was announced the day before yesterday. The core operating profit was raised from the previous estimate of 30 billion yen to 43.2 billion yen, while the previous term had a loss of 133 billion yen. In the North America segment, the treatment for advanced prostate cancer "Orgovix" appears to be exceeding expectations. Although impairment losses will be recognized, the operating profit has also been raised from 21 billion yen to 28.8 billion yen, significantly exceeding the market consensus of approximately 15 billion yen.
Sumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales
The Nikkei average is up about 50 yen, and after buying, it shows heavy movement at the upper levels = 30 days before the morning session.
On the 30th at 10:08 AM, the Nikkei average stock price fluctuated around 35,890 yen, down about 50 yen compared to the previous trading day. At 9:09 AM, it reached 36,023 yen 24 sen, up 183 yen 25 sen. In the U.S. market on the 29th, the announcement by the U.S. government to reduce tariffs on imported components for completed vehicles produced domestically was well received, leading to the Dow Inc rising for the sixth consecutive day and a rebound in the Nasdaq Composite Index. Japanese stocks also saw buying ahead of the rise in U.S. stocks. However, after the initial buying settled down.